key: cord-0710738-h1sura49 authors: Lai, J.; German, J. R.; Hong, F. H.; Tai, S.- H. S.; McPhaul, K. M.; Milton, D. K.; Group, University of Maryland StopCOVID Research title: Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19 date: 2021-12-02 journal: nan DOI: 10.1101/2021.12.01.21267147 sha: e630ea14dcdd23d1291921efebbbd0131f2bb886 doc_id: 710738 cord_uid: h1sura49 Background: Saliva is an attractive sample for detecting SARS-CoV-2 because it is easy to collect and minimally invasive. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs. Methods: We recruited and followed close contacts of COVID-19 cases for up to 14 days from their last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS) and saliva every two or three days. Ct values and frequency of viral detection by MTS and saliva were compared. Logistic regression was used to estimate the probability of detection by days since symptom onset for the two sample types. Results: We enrolled 58 contacts who provided a total of 200 saliva and MTS sample pairs; 14 contacts (13 with symptoms) had one or more positive samples. Overall, saliva and MTS had similar rates of viral detection (p=0.78). Although Ct values for saliva were significantly greater than for MTS (p=0.014), Cohen's Kappa demonstrated substantial agreement ({kappa}=0.83). However, sensitivity varied significantly with time relative to symptom onset. Early in the course of infection (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of detecting viral RNA compared to MTS. After day 2, there was a non-significant trend to greater sensitivity using MTS samples. Conclusion: Saliva and MTS specimens demonstrated high agreement, making saliva a suitable alternative to MTS nasal swabs for COVID-19 detection. Furthermore, saliva was more sensitive than MTS early in the course of infection, suggesting that it may be a superior and cost-effective screening tool for COVID-19. The U.S. Centers for Disease Control and Prevention (CDC) recommend the use of upper 56 respiratory specimens, including but not limited to nasopharyngeal, mid-turbinate nasal, anterior 57 nasal and saliva specimens for the initial diagnosis of COVID-19 [1] . Although nasopharyngeal 58 swabs (NPS) are considered to be the standard for the detection of COVID-19 by most 59 researchers, collection requires the use of trained professionals, can cause discomfort to the 60 patients, and may pose greater risks to healthcare workers during sample collection [1] [2] [3] [4] . Mid-61 turbinate swabs (MTS) are sometimes used as an alternative to NPS in an effort to reduce patient 62 discomfort and occupational exposures to healthcare workers [4] [5] [6] . Compared to swab-based 63 collection, saliva is even less invasive, more affordable, and can be self-collected with minimal 64 or no supervision [1, 7, 8] . 65 66 Existing studies focusing on the sensitivity of NPS compared to MTS, and NPS compared to 67 saliva have produced contradictory results [2, 4, [9] [10] [11] . Few studies directly compare saliva and 68 MTS specimens. Previous studies demonstrated that pre-symptomatic transmission results in 69 higher secondary attack rates for both symptomatic and asymptomatic transmission [12, 13] . 70 However, most of the existing studies only looked at detection of symptomatic cases after 71 symptom onset [2, 4, 9, 10] and few looked at detection sensitivity starting with the pre-72 symptomatic period. Therefore, a study that conducts a direct comparison of MTS and saliva, 73 including an assessment of sensitivity over time (starting during the pre-symptomatic period) is 74 critical to identifying optimally sensitive methods for early detection and effective control of 75 SARS-CoV-2 transmission. 76 77 The purpose of this study was to compare the sensitivity of MTS and saliva specimens for 78 detecting SARS-CoV-2 by actively following close contacts of COVID-19 cases and collecting 79 MTS and saliva samples for real-time reverse transcription polymerase chain reaction (RT-PCR) 80 during their post-exposure quarantine period. 81 82 Study population 84 We analyzed MTS and saliva sample data from individuals who reported close contact with 85 confirmed COVID-19 cases as part of the University of Maryland StopCOVID study [14] from 86 May 2020 to April 2021. 87 88 Questionnaire and sample collection 89 Participants were followed every two or three days for up to 14 days from their last exposure or 90 until SARS-CoV-2 was detected in their samples. If one or more of their screening samples 91 became positive, results were confirmed by an appropriate clinical diagnostic test and they were 92 recruited to participate in the exhaled breath aspect of the study that also involved the collection 93 of saliva and MTS [14] . On each day of sample collection, participants answered an online 94 questionnaire to update their current symptoms and medications. For those who reported having 95 any symptom, they also reported their symptom onset date (i.e., "When did you begin to feel 96 sick?"). 97 98 The symptoms checklist in the baseline and follow-up questionnaires, as previously described 99 [14], included runny nose, stuffy nose, sneezing, sore throat, earache, malaise, headache, muscle 100 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 2, 2021. and/or joint ache, sweat/feverish/chills, nausea, loss of appetite, vomiting, abdominal pain or 101 diarrhea, chest tightness, shortness of breath, and cough. Participants self-reported for each of 102 these 16 symptoms on a scale of 0 to 3 (0 = "no symptoms," 1 = "just noticeable," 2 = "clearly 103 bothersome from time to time, but didn't stop me from participating in activities," 3 = "quite 104 bothersome most or all of the time and stopped me from participating in activities" onset for the two sample types. We also created a plot using the LOESS (locally weighted 145 smoothing) method with 95% confidence interval for the change of Ct values by days since 146 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. We enrolled 58 individuals with known close contact with an active COVID-19 case. Figure 1a ). The Ct values for saliva were on average slightly but significantly greater than 189 for MTS samples (mean difference = 0.64, p=0.01) among all 58 participants (Figure 1b and 190 Figure S1 ), partially reflecting the difference in their input amounts. 191 192 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. (Figure 2A ). 196 197 Among symptomatic participants who had one or more positive saliva or MTS samples, the 198 probability (sensitivity) of detecting viral RNA in saliva samples was 91% (10/11) from day -3 199 to day 2 (Table 3) , was 89% (16/18) from day 3 through 8, and declined significantly thereafter 200 ( Figure 2B and Figure S2 ). The probability of detecting virus in MTS samples from day -3 201 through day 2 was lower 45% (5/11), was 94% (17/18) from day 3 through 8, and then dropped 202 off again. Early in the course of infection (days -3 through 2) saliva had 12 times the odds of 203 being positive compared to MTS (Odds ratio = 12, 95% CI: 1.2, 130). Although there was a 204 trend toward greater sensitivity using MTS than saliva samples after day 2 post onset of 205 symptoms, the difference was not statistically significant (Table 3) . 206 207 Asymptomatic case 208 Only one participant from our study population was an asymptomatic case. They provided one 209 pair of saliva and MTS samples, both of which were positive, with an average Ct value of 25.8 210 for MTS and 34.7 for saliva (Table S4) . 211 212 213 Early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal 215 swabs (MTS). We found that the optimal performance of saliva was in the pre-symptomatic 216 period and was more sensitive than MTS before symptom onset. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 2, 2021. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 2, 2021. ; https://doi.org/10.1101/2021.12.01.21267147 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 2, 2021. ; https://doi.org/10.1101/2021.12.01.21267147 doi: medRxiv preprint CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 2, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 2, 2021. ; https://doi.org/10.1101/2021.12.01.21267147 doi: medRxiv preprint Interim Guidelines for Collecting and Handling 311 of Clinical Specimens for COVID-19 Testing Change in Saliva RT-PCR Sensitivity Over 315 the Course of SARS-CoV-2 Infection Performance of Saliva Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a 319 Systematic Review and Meta-analysis Sensitivity of midturbinate versus 321 nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 322 (SARS-CoV-2) Performance of saliva and mid-turbinate swabs for 324 detection of the beta variant in South Africa Swabs Collected by Patients or Health Care Workers for SARS The New England journal of medicine 2020 Saliva as a gold-standard sample for 329 SARS-CoV-2 detection SalivaDirect: A simplified and flexible platform 331 to enhance SARS-CoV-2 testing capacity Comparing Nasopharyngeal and Mid-Turbinate Nasal 333 Swab Testing for the Identification of SARS-CoV-2 Saliva is more sensitive than nasopharyngeal or nasal 336 swabs for diagnosis of asymptomatic and mild COVID-19 infection The Sensitivity and Costs of 339 Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A 340 Systematic Review and Meta-analysis Presymptomatic Transmission in SARS-CoV-2 Outbreak The role of asymptomatic and 346 pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review Infectious SARS-CoV-2 in Exhaled Aerosols 349 and Efficacy of Masks During Early Mild Infection ThermoFisher Scientific. TaqPath TM COVID-19 Combo Kit and TaqPath TM Combo Kit Advanced* Instructions for Use Generalized additive models for medical research Core Team. R: A Language and Environment for Statistical Computing The REDCap consortium: Building an international 358 community of software platform partners The Infectious Diseases Society of America 361 Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing Swabs Collected by Patients or Health Care Workers for 364 SARS-CoV-2 Testing Saliva offers a sensitive, specific and non-invasive 368 alternative to upper respiratory swabs for SARS-CoV-2 diagnosis Factors Influencing COVID-19 Testing: A 371 Qualitative Study in Bhutan Saliva testing for severe acute respiratory syndrome coronavirus 2 in 374 children Comparison of Nasal Swabs with 376 Nose Blowing for Community-Based Pneumococcal Surveillance of Healthy Children Increased SARS-CoV-2 Testing Capacity 379 with Pooled Saliva Samples